Stock Market News
Physiomics narrows losses despite sliding revenues
Computational biology services provider Physiomics saw revenue drop 57% to £74,000 over the six months leading to 31 December, but the Oxford-based firm believed that a resurgence of interest in rational drug design was just around the corner.
Despite seeing revenue fall throughout the half, Physiomics shrank its operating loss to £220,000 from the £263,000 posted a year earlier.
Physiomics pointed out that as oncology pipelines had increased 45% over the last decade, pushing global spend on oncology drugs to $113bn as of 2016, with a 6-9% expansion on that figure every year until 2022, it felt there would be an increased acceptance of the value of modelling the effects of oncology treatments rather than "falling back on more traditional, often heuristic, methods."
The company's Virtual Tumour platform was designed to aid clients in making predictions on the efficacy of combinations of new and old cancer drugs in both pre-clinical and clinical settings, and is also capable of incorporating data from biomarkers to allow predictions to be made for patient subpopulations, making it well positioned to take advantage of the improving trends.
Physiomics, which also won new contracts with two major pharmaceutical clients in January and February, said first-half performance was in line with management expectations given the significant resource that was expended to complete its deal with Merck KGaA, and given that the revenue flows from the aforementioned deal didn't begin until January.
Loss per share improved from 0.50p to 0.34p.
As of 1000 GMT, shares had dropped 5.07% to 6.45p.
Despite seeing revenue fall throughout the half, Physiomics shrank its operating loss to £220,000 from the £263,000 posted a year earlier.
Physiomics pointed out that as oncology pipelines had increased 45% over the last decade, pushing global spend on oncology drugs to $113bn as of 2016, with a 6-9% expansion on that figure every year until 2022, it felt there would be an increased acceptance of the value of modelling the effects of oncology treatments rather than "falling back on more traditional, often heuristic, methods."
The company's Virtual Tumour platform was designed to aid clients in making predictions on the efficacy of combinations of new and old cancer drugs in both pre-clinical and clinical settings, and is also capable of incorporating data from biomarkers to allow predictions to be made for patient subpopulations, making it well positioned to take advantage of the improving trends.
Physiomics, which also won new contracts with two major pharmaceutical clients in January and February, said first-half performance was in line with management expectations given the significant resource that was expended to complete its deal with Merck KGaA, and given that the revenue flows from the aforementioned deal didn't begin until January.
Loss per share improved from 0.50p to 0.34p.
As of 1000 GMT, shares had dropped 5.07% to 6.45p.
Related share prices |
---|
Physiomics (PYC) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price